Acceptability, Facilitators, and Barriers of Long-Acting Injectable Cabotegravir/Rilpivirine Among Youth With HIV in the United States.

Saved in:
Bibliographic Details
Title: Acceptability, Facilitators, and Barriers of Long-Acting Injectable Cabotegravir/Rilpivirine Among Youth With HIV in the United States.
Authors: Unternaher J; Division of Infectious Diseases, Children's National Hospital, Washington, D.C.. Electronic address: junternahe@childrensnational.org., Craddock C; Department of Global Health, The George Washington University Milken Institute School of Public Health, Washington, D.C., Koay WLA; Department of Pediatrics, Division of Infectious Diseases, Medical University of South Carolina, Charleston, South Carolina., Barnett AP; Division of Infectious Diseases, Children's National Hospital, Washington, D.C.; Division of Psychology and Behavioral Health, Children's National Hospital, Washington, D.C., Williams T; Division of Infectious Diseases, Children's National Hospital, Washington, D.C., Rakhmanina N; Division of Infectious Diseases, Children's National Hospital, Washington, D.C.; Department of Pediatrics, The George Washington University School of Medicine, Washington, D.C.; Technical Strategies and Innovation, Elizabeth Glaser Pediatric AIDS Foundation, Washington, D.C.
Source: The Journal of adolescent health : official publication of the Society for Adolescent Medicine [J Adolesc Health] 2025 Dec; Vol. 77 (6), pp. 1135-1143. Date of Electronic Publication: 2025 Sep 18.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 9102136 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-1972 (Electronic) Linking ISSN: 1054139X NLM ISO Abbreviation: J Adolesc Health Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1879-1972
DOI:10.1016/j.jadohealth.2025.07.025